Trial Profile
Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE-AD3
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 16 Jul 2023 This trial has been completed in Germany (End date: 12 Jul, 2023), according to European Clinical Trials Database record.
- 14 Jul 2023 Status changed from active, no longer recruiting to completed.
- 05 Apr 2023 Results published in the Journal of Dermatological Treatment